Scarica l'app Stockscreener
22.29
1.94%
-0.44
Dopo l'orario di chiusura:
22.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$22.73
Aprire:
$22.4
Volume 24 ore:
1.31M
Relative Volume:
0.70
Capitalizzazione di mercato:
$2.53B
Reddito:
$70.92M
Utile/perdita netta:
$-342.21M
Rapporto P/E:
-5.9213
EPS:
-3.7644
Flusso di cassa netto:
$-304.30M
1 W Prestazione:
-2.92%
1M Prestazione:
-3.34%
6M Prestazione:
-23.64%
1 anno Prestazione:
+12.46%
Intervallo 1D:
$21.99
$22.60
Intervallo di 1 settimana:
$21.99
$23.84
Portata 52W:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
22.29 | 2.58B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Reiterato | Wedbush | Outperform |
| 2025-12-03 | Iniziato | William Blair | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Viridian at Wells Fargo conference: launch gains and pipeline build By Investing.com - Investing.com Canada
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - The Globe and Mail
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Viridian Therapeutics Inc (VRDN:UW): Stock Price, Quote and News - BNN Bloomberg
260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP - MarketBeat
Deep Track Capital, LP Trims Viridian Therapeutics (VRDN) Stake in Strategic Rebalancing - GuruFocus
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares By Investing.com - Investing.com Canada
Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares - Investing.com
Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares - MarketBeat
Viridian Therapeutics (VRDN) legal chief sells 14,212 shares - Stock Titan
Viridian (VRDN) Latest Quarter: Reported Results Sit Close to Expectations; Session Move: The Stock Ends Down 1.21% in Latest TradingEarnings Preview - Vinanet
Steven Cohen’s Point72 discloses Viridian stake (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) Could Be 83% Undervalued On Fresh Earnings Numbers - Sahm
ETFs Investing in Viridian Therapeutics, Inc. Stocks - TradingView
Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Viridian (NASDAQ: VRDN) insider to sell 14,212 shares in August 2026 - Stock Titan
GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian (NASDAQ: VRDN) CMO acquires 40K shares via option - Stock Titan
93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc. - MarketBeat
1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC - MarketBeat
Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Viridian Therapeutics Stock Price Forecast. Should You Buy VRDN? - StockInvest.us
Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund - Stock Titan
Kynam Capital group (VRDN) discloses shared power over 6.45M Viridian shares - Stock Titan
T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G - Stock Titan
Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing - Stock Titan
Viridian Therapeutics, Inc. (1S1) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Trading the Move, Not the Narrative: (VRDN) Edition - news.stocktradersdaily.com
Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside - TradingView
Viridian Therapeutics (VRDN) Gets a Buy from Truist Financial - The Globe and Mail
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22% - simplywall.st
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Viridian Therapeutics (VRDN) Stock Analysis: Unpacking The 58.82% Potential Upside - DirectorsTalk Interviews
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Have Been Cutting Their Estimates - 富途牛牛
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Arrowstreet Capital Limited Partnership Has $455,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
VRDN Maintained by RBC Capital -- Price Target Raised to $36.00 - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says - marketscreener.com
State Street Corporation (NASDAQ: VRDN) discloses 5.5% Viridian Therapeutics ownership - Stock Titan
RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating - Moomoo
Truist Financial Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $41 - Moomoo
William Blair Maintains Viridian Therapeutics(VRDN.US) With Buy Rating - Moomoo
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):